Article

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

2011-01-01

Abstract excerpt

No abstract is available from the source.

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 49275e88-730a-5fa2-bfb7-f8c0f8927c9c
DOI: 10.1016/j.breastdis.2011.03.043

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trialDOI 10.1016/j.breastdis.2011.03.043Read

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trialSemantic proximity Read

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trialSemantic proximity Read

Association of BRCA mutation status with the efficacy of poly (ADP-ribose) polymerase inhibitors in cancer: A systematic review and meta-analysis.Semantic proximity Read

Development of poly(ADP-ribose) polymerase inhibitors in the treatment of BRCA-mutated breast cancer.Semantic proximity Read

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from <i>BRCA</i> Mutation CarriersSemantic proximity Read

Olaparib for the treatment of breast cancer.Semantic proximity Read

Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations.Semantic proximity Read

Poly(ADP-ribose) polymerase inhibition: a new direction for BRCAand triple-negative breast cancer?Semantic proximity Read

Poly(ADP-Ribose) Polymerase InhibitorsSemantic proximity Read

Olaparib: A Novel Therapy for Metastatic Breast Cancer in Patients With a BRCA1/2 MutationSemantic proximity Read

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.Semantic proximity Read

Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in BRCA-mutated HER2-negative metastatic or advanced breast cancer: a network meta-analysis.Semantic proximity Read